



BY IEHP PHARMACEUTICAL SERVICES DEPARTMENT

- To: IEHP Pharmacy Network
- From: IEHP Pharmaceutical Services Department
- Date: November 1, 2022
- **Subject:** COVID-19: Test to Treat Monoclonal Antibodies

The <u>COVID-19 Test to Treat</u> sites offer Members to get tested and if they are eligible for treatment (i.e. within the five-day from the onset) offers a prescription on the same day. The COVID-19 oral antiviral pills currently include Lagevrio (Molnupiravir) and Paxlovid (Nirmatrelvir/Ritonavir). Pharmacies that are not participating as a COVID-19 Test to Treat site may also furnish oral antivirals. More information can be found at the following link: <u>https://www.fda.gov/news-events/press-</u> <u>announcements/coronavirus-covid-19-update-fda-authorizes-pharmacists-prescribepaxlovid-certain-limitations</u>

<u>Please keep in mind that for members who are **beyond the five-day treatment window** for oral antivirals **should be referred to a monoclonal antibody infusion** <u>facilities.</u></u>

COVID-19 Infusion Treatment by Infusion Sites can be found at the link below: <u>http://www.iehp.org/en/providers/plan-updates?target=coronavirus-advisory</u>

For more information about COVID-19 Test to Treat mAB (Monoclonal Antibodies), please visit: <u>https://www.cdc.gov/coronavirus/2019-ncov/your-health/treatments-for-severe-illness.html</u>

If you have any additional questions, please feel free to contact us at (909) 890-2049 between 8:00 AM -5:00 PM on IEHP business days. Thank you for your attention to this matter.